Early stage potential Naked Biome is a microbiome based skin therapeutics company with a completed Phase IB for acne using a topical live biologic. This indicates a proof of concept in a dermatology space and a potential for novel partnerships or licensing opportunities around skin disease indications.

Clinical validation Positive safety and efficacy trends in acne from a Phase IB study suggest value in advancing collaborations with pharma or biotech firms seeking early clinical data, co-development, or milestone-driven partnerships in dermatology.

Funding and runway With $17M in funding and revenue under $1M, Naked Biome is positioned for growth but may seek strategic investments or partnerships to scale clinical programs, manufacturing, and go-to-market activities in skin therapeutics.

Low headcount, high focus A 0-1 employee size signals a very early-stage operation with potential for strong outsourcing and partnerships across CROs, DMOs, and contract manufacturing, offering sales opportunities around platform licensing, collaboration agreements, or managed services.

Digital footprint plus platform The company emphasizes a proprietary genomics platform for skin therapy and maintains a digital stack including WordPress and OpenGraph, suggesting opportunities to offer cloud-enabled data analytics, platform partnerships, or software services to support their discovery and development efforts.